JiangXi Tianxin Pharm Co Ltd Working Capital to Net Assets Ratio
JiangXi Tianxin Pharm Co Ltd working capital to net assets ratio. JiangXi Tianxin Pharm Co Ltd (603235) has a Working Capital to Net Assets ratio of 44.3% as of March 2026. Working capital of CN¥2.24 Billion (current assets of CN¥2.79 Billion minus current liabilities of CN¥549.73 Million) is measured against net assets of CN¥5.06 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check JiangXi Tianxin Pharm Co Ltd (603235) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of JiangXi Tianxin Pharm Co Ltd (2020–2025)
Working capital to net assets ratio of JiangXi Tianxin Pharm Co Ltd from 2020 to 2025. This chart shows how JiangXi Tianxin Pharm Co Ltd's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2020 to 2025. As of March 2026, the ratio stands at 44.3%, reflecting working capital of CN¥2.24 Billion against net assets of CN¥5.06 Billion CNY. See JiangXi Tianxin Pharm Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
JiangXi Tianxin Pharm Co Ltd Working Capital to Net Assets Ratio by Year (2020–2025)
JiangXi Tianxin Pharm Co Ltd working capital to net assets ratio by year from 2020 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for JiangXi Tianxin Pharm Co Ltd from 2020 to 2025, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of JiangXi Tianxin Pharm Co Ltd.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 43.7% | CN¥2.15 Billion | CN¥4.92 Billion | CN¥2.78 Billion | CN¥635.59 Million | ▼ -3.7 pp |
| 2024 | 47.3% | CN¥2.19 Billion | CN¥4.62 Billion | CN¥2.70 Billion | CN¥509.78 Million | ▼ -15.5 pp |
| 2023 | 62.8% | CN¥2.66 Billion | CN¥4.23 Billion | CN¥3.12 Billion | CN¥461.33 Million | ▼ -7.5 pp |
| 2022 | 70.4% | CN¥2.86 Billion | CN¥4.06 Billion | CN¥3.17 Billion | CN¥311.18 Million | ▲ +23.1 pp |
| 2021 | 47.3% | CN¥902.34 Million | CN¥1.91 Billion | CN¥1.58 Billion | CN¥677.06 Million | ▲ +33.7 pp |
| 2020 | 13.5% | CN¥156.24 Million | CN¥1.15 Billion | CN¥1.65 Billion | CN¥1.49 Billion | — |